Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Priyadarshan Bajpayi

Psychiatry Massapequa, NY Medical Doctor

NPI 1699087148 CMS profile 838207

5550 Merrick Rd, Ste 300, Massapequa, NY 11758

Open in the dashboard

General payments

$297,294

1,931 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Priyadarshan Bajpayi of Massapequa, NY is reported in the CMS Open Payments database as having received $297,294 across 1,931 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81,642 312
2024 General $64,660 312
2023 General $66,962 266
2022 General $52,122 301
2021 General $23,333 334
2020 General $5,693 231
2019 General $2,881 175

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priyadarshan Bajpayi
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Priyadarshan Bajpayi were reported at $81,642. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Priyadarshan Bajpayi Psychiatry median Middle half National median
2019 $2,881 $184 $59–$605 $163
2020 $5,693 $119 $36–$372 $114
2021 $23,333 $143 $43–$576 $132
2022 $52,122 $153 $50–$590 $149
2023 $66,962 $170 $56–$651 $160
2024 $64,660 $179 $57–$673 $164
2025 $81,642 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $105,642 203 payments
  2. Otsuka America Pharmaceutical, Inc. $43,257 195 payments
  3. Janssen Pharmaceuticals, Inc $34,834 123 payments
  4. Axsome Therapeutics, Inc. $34,611 49 payments
  5. ITI, Inc. $21,740 128 payments
  6. AbbVie, Inc. $21,353 134 payments
  7. Supernus Pharmaceuticals, Inc. $14,508 70 payments
  8. Tris Pharma Inc $4,317 23 payments
  9. Lundbeck LLC $3,632 235 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $1,906 108 payments
  11. Other $11,493 663 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $193,020 93 payments
  2. Food and Beverage $41,748 1,752 payments
  3. Consulting Fee $35,545 13 payments
  4. Honoraria $15,426 6 payments
  5. Travel and Lodging $11,233 52 payments
  6. Education $322 15 payments
Products named General payments · program years 2019–2025
  1. LYBALVI Cns $104,449 173 payments
  2. LYBALVI Cns $103,172 112 payments
  3. LYBALVI Cns $102,764 94 payments
  4. LYBALVI Cns $102,764 94 payments
  5. REXULTI $39,545 128 payments
  6. SPRAVATO $34,394 107 payments
  7. Auvelity $34,172 40 payments
  8. VRAYLAR $20,834 111 payments
  9. CAPLYTA $20,044 49 payments
  10. Qelbree $14,018 33 payments
  11. Other $49,492 1,781 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

4,831

Median for Psychiatry: 574

Drug cost

$711,656

Median for Psychiatry: $27,624

Branded share of claims

22.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 131 $252,216
Austedo Deutetrabenazine Brand 11 $157,849
Rexulti Brexpiprazole Brand 44 $64,424
Caplyta Lumateperone Tosylate Brand 28 $52,284
Vraylar Cariprazine Hcl Brand 22 $31,132
Lybalvi Olanzapine/Samidorphan Malate Brand 12 $20,362
Trintellix Vortioxetine Hydrobromide Brand 28 $19,029
Mounjaro Tirzepatide Brand 13 $13,751
Lurasidone Hcl Generic 30 $7,808
Adzenys Xr-Odt Amphetamine Brand 15 $7,356

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$1,024,334

Medicare's payments for the services billed

Medicare patients

785

Average age 66

Services billed

13,947

498 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 64%
Arthritis 49%
Diabetes 30%
Ischemic heart disease 27%
Osteoporosis 18%
COPD 17%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYBALVI
$19,769 12 —
Qelbree
$14,003 — —
Auvelity
$12,112 — —
SPRAVATO
$8,568 131 —
REXULTI
$6,112 44 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

1,931 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record